Pegsitacianine clinical trials
Also written ONM-100.
How each study uses pegsitacianine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegsitacianine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
OncoNano Medicine, Inc. (3) · University of Texas Southwestern Medical Center (1)
Studies
Open first, then newest update. How each study uses pegsitacianine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)RecruitingPhase 2University of Texas Southwestern Medical CenterNCT05576974Written as Pegsitacianine
- A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung MalignanciesCompletedPhase 2OncoNano Medicine, Inc.NCT05048082Written as pegsitacianine
- A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri MetsCompletedPhase 2OncoNano Medicine, Inc.NCT04950166Written as pegsitacianine
- A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of CancerCompletedPhase 2OncoNano Medicine, Inc.NCT03735680Written as ONM-100
Codes
What other systems call pegsitacianine · ClinicalTrials.gg INT014833
- UNII (FDA) 49X2Q41T99PEGSITACIANINEOne source FDA
- NCI Thesaurus C158750PegsitacianineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 49X2Q41T99 | PEGSITACIANINE | One source FDA |
| NCI Thesaurus | C158750 | Pegsitacianine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.